title: Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.
abstract: The concepts of partial recovery and remission have become increasingly important for the evaluation of the effectiveness of schizophrenia therapeutics. The relationship of baseline symptoms and changes in symptoms to remission of psychosis was evaluated. Fifty-six outpatients with residual schizophrenia completed a double-blind trial of olanzapine versus haloperidol and were then enrolled into a one-year open-label trial of olanzapine. Out of these 56 subjects, 13 (23%) met remission criteria at the beginning of the open-label treatment and were excluded. During the one-year study, 7/43 (16%) subjects met remission criteria. These subjects had significantly lower baseline ratings for tardive dyskinesia (TD) than subjects who did not achieve remission (1.8 +/- 1.5 vs. 4.2 +/- 4.6, P = 0.03). As expected, remitted subjects had significantly greater improvements in Brief Psychiatric Rating Scale total scores, positive subscale scores and scale for the Assessment of Negative Symptoms total scores. Remitted subjects also experienced a significantly greater improvement in depressive symptoms (P = 0.001), activation (P = 0.005), and Clinical Global Impressions scores (P < 0.001), as well as greater improvements in extrapyramidal symptoms (P = 0.007) and TD (P < 0.001). These results suggest that the relationship of depressive symptoms and improved side effects to the construct of remission in schizophrenia may deserve special attention. Future studies should aim to relate remission criteria to functional outcomes, cognition, and other important symptom domains.
authors.affiliation: Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD, USA. dkelly@mprc.umaryland.edu
authors.forename: D L
authors.initials: DL
authors.lastname: Kelly
authors.forename: E
authors.initials: E
authors.lastname: Weiner
authors.forename: M P
authors.initials: MP
authors.lastname: Ball
authors.forename: R P
authors.initials: RP
authors.lastname: McMahon
authors.forename: W T
authors.initials: WT
authors.lastname: Carpenter
authors.forename: R W
authors.initials: RW
authors.lastname: Buchanan
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000175:diagnosis*; D001569:Benzodiazepines / Q000627:therapeutic use; D003863:Depression / Q000175:diagnosis*; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011788:Quality of Life; D012074:Remission Induction; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy; D012720:Severity of Illness Index
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine